News articles featuring quotes from Real Endpoints

<>

January 27, 2019

PharmExec

Precision Financing of Durable, Potentially Curative Therapies

by Jane Barlow, MD, MPH, MBA

Durable and potentially curative gene therapies and cellular treatments are being developed for a wide range of conditions. While a boon for patients, this could prove a financial bane for payers due to the fact that years of taking and reimbursing medications is condensed into a single, much larger, upfront payment at the time of an abbreviated treatment.

read full article >

October 16, 2018

PharmaVoice

Jeff Berkowitz Takes Helm of Real Endpoints

by PharmaVoice

Real Endpoints, which provides development and implementation of proprietary tools, has named Jeff Berkowitz as CEO and member of the board of directors. Most recently, Mr. Berkowitz served as an executive VP at UnitedHealth Group, CEO of it Optum International business, and as a strategic leader of OptumRx, its PBM, Mr. Berkowitz is a PharmaVOICE Red Jacket - 2014.

Read full article >

September 13, 2018

Real Endpoints Appoints Jeff Berkowitz, CEO and Director

by Real Endpoints LLC

Real Endpoints (RE), a leader in the development and implementation of proprietary tools to strengthen pharmaceutical market access for an evolving healthcare landscape, announced today that Jeff Berkowitz, a 20-year veteran of the pharmaceutical, drug distribution, pharmacy and payer industries, has joined the company as CEO and member of the board of directors. Jeff is one of the rare executives whose.....

read full press release >

July 25, 2018

Managed Care

Must Sky-High Prices ‘Come on Down’ Before the Price Is Right?

by Richard Mark Kirkner

The first gene therapy to treat an inherited disease is out of the gate, but with a very high price tag. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation?

read full article >

June 15, 2018

BioCentury

Safer Harbor

by Steve Usdin

FDA guidance released on June 12 broadens a safe harbor that allows medical product manufacturers to communicate with payers, PBMs, formulary committees and similar entities. A primary goal is to make it easier to base payments on outcomes not mentioned on product labels, but there could be broader effects in the loosened restrictions oncommunications between medical product developers and payers.

read full article >

April 9, 2018

BioCentury

Part D Sour Spot

by Steve Usdin

A law that comes into effect next year will squeeze profits from moderately priced drugs that treat common, chronic conditions and increase economic incentives to develop high priced medicines for rare or acute life-threatening diseases. Manufacturers of drugs to treat common, chronic conditions will be especially hard hit.

read full article >